Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
暂无分享,去创建一个
Marc P. Bonaca | G. Hankey | E. Braunwald | D. Morrow | S. Murphy | J. Mohr | B. Scirica | M. Alberts | S. Goto | S. Ameriso
[1] Marc P. Bonaca,et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.
[2] C. Coffey,et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. , 2012, The New England journal of medicine.
[3] Y. Shinohara,et al. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[4] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[5] E. Topol,et al. Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2012, Stroke.
[6] Craig D Williams,et al. Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke , 2012, Nature Reviews Neurology.
[7] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[8] Deepak L. Bhatt,et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis , 2010, European heart journal.
[9] Marc P. Bonaca,et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.
[10] Marc P. Bonaca,et al. SCH 530348: a novel oral thrombin receptor antagonist. , 2009, Future cardiology.
[11] Vivian Gu,et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.
[12] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[13] Deepak L. Bhatt,et al. One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.
[14] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[15] A. Algra,et al. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke , 1997, Journal of the Neurological Sciences.
[16] H. Diener,et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.
[17] David Lee Gordon,et al. Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.
[18] A. Lowenthal. The European Stroke Prevention Study , 1988, Acta neurologica Belgica.